Evidence map›Paper›PMID 26261424›Full record

ArticleJournal of pain research2015

Anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow nucleated cells: a case series.

Christopher J Centeno, John Pitts, Hasan Al-Sayegh, Michael D Freeman

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Journal of pain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03517761 narecruitingnot on this mapstarted 2018, after this paper: background citation

A Single-Blinded, Randomized Controlled Trial Evaluating the Use of Bone Marrow Concentrate for the Treatment of Alar, Accessory, and Transverse Ligament Injuries

TypeinterventionalSponsorRegenexx, LLCRan2018 to 2030Enrolled80ConditionsCraniocervical InjuriesArmsBone Marrow Concentrate treatment, Sham Control
NCT03557606 withdrawnnot on this mapstarted 2018, after this paper: background citation

A Case Series Evaluating the Use of Bone Marrow Concentrate for the Treatment of Alar, Accessory, and Transverse Ligament Injuries

TypeobservationalSponsorRegenexx, LLCRan2018 to 2023Enrolled0ConditionsCraniocervical InjuriesArmsAlar treatment with BMC using anterior approach
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Mechanically superior matrices promote osteointegration and regeneration of anterior cruciate ligament tissue in rabbits.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Christopher J CentenoCenteno-Schultz Clinic, Broomfield, CO, USA ; Regenerative Sciences, LLC., Broomfield, CO, USA.
John PittsCenteno-Schultz Clinic, Broomfield, CO, USA.
Hasan Al-SayeghRegenerative Sciences, LLC., Broomfield, CO, USA.
Michael D FreemanPublic Health Department, Oregon Health and Science University, Portland, OR, USA.
Centeno-Schultz Clinic · USOregon Health & Science University · USRegenerative Sciences Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis was a prospective case series designed to investigate treatment for anterior cruciate ligament (ACL) tears using an injection of autologous bone marrow concentrate.

methodsConsecutive adult patients presenting to a private outpatient interventional musculoskeletal and pain practice with knee pain, ACL laxity on exam, and magnetic resonance imaging (MRI) evidence of a grade 1, 2, or 3 ACL tears with less than 1 cm retraction were eligible for this study. Eligible patients were treated with an intraligamentous injection of autologous bone marrow concentrate, using fluoroscopic guidance. Pre- and postprocedural sagittal MRI images of the ACLs were analyzed using ImageJ software to objectively quantify changes between pre- and posttreatment scans. Five different types of measurement of ACL pixel intensity were examined as a proxy for ligament integrity. In addition pain visual analog scale (VAS) and Lower Extremity Functional Scale (LEFS) values were recorded at baseline and at 1 month, 3 months, 6 months, and annually postinjection. Objective outcomes measured were pre- to post-MRI measurement changes, as analyzed by the ImageJ software. Subjective outcomes measured were changes in the VAS and LEFS, and a self-rated percentage improvement.

resultsSeven of ten patients showed improvement in at least four of five objective measures of ACL integrity in their postprocedure MRIs. In the entire study group, the mean gray value, median, raw integrated density, and modal gray value all decreased toward low-signal ACLs (P=0.01, P=0.02, P=0.002, and P=0.08), indications of improved ligament integrity. Seven of ten patients responded to the self-rated metrics follow up. The mean VAS change was a decrease of 1.7 (P=0.25), the mean LEFS change was an increase of 23.3 (P=0.03), and mean reported improvement was 86.7%.

conclusionBased on this small case series, autologous bone marrow concentrate shows promise in the treatment of grade 1, 2, and possibly grade 3 ACL tears without retraction. Further investigation using a controlled study design is warranted.

Indexed as

anterior cruciate ligament injurybone marrow concentrateknee instabilitymesenchymal stem cellsregenerative therapy

Identifiers

PMID26261424
PMCPMC4527573
OpenAlexW1007270634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.